Research Article

Novel Application of Radotinib for the Treatment of Solid Tumors via Natural Killer Cell Activation

Figure 4

A comparison of the cytolytic activity of radotinib and imatinib mesylate. A comparison of the cytolytic activity of radotinib and imatinib mesylate, a TKI for treating CML, against Fas-expressing A549 cells was performed using radotinib- or imatinib mesylate-treated PBLs as effector cells and A549 cells as target cells in a cytotoxicity assay. Data are reported as . All values were analyzed by unpaired Student’s -tests using GraphPad Prism 5. and . All data presented are representative of three independent experiments.